Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

GLP-1 RAs are known to delay gastric emptying, raising concerns about regurgitation, aspiration, and airway compromise during ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

The Study will also include use of certain glucagon-like peptide-1 ("GLP-1") receptor specific antibodies detectable ... for the content of linked third party websites. We are not an agent for these ...

On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

In obesity and diabetes, the leading GLP-1 drugs, which include Novo’s Wegovy and Ozempic, require injections once a week.

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

A new guideline released on World Diabetes Day will give GPs and other health professionals positive recommendations for optimal diabetes management ...